US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...

Q4 2024 Earnings Call Transcript March 27, 2025 VirTra, Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, ...

The climate action group Just Stop Oil has announced it is to disband at the end of April. Its activists have been derided as ...

The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...

Q4 2024 revenue was $5.4 million, compared to $10.9 million in Q4 2023, impacted by federal budget delays and grant distribution pauses. For the full year 2024, revenue totaled $26.4 million, down ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

Unity CEO Matthew Bromberg wants to bring stability and trust back to the company's relations with game developers.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...

Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome (PWS), breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, ...

The new-look XR smart glasses will allow technicians to receive remote support from their service desk with a visual aid.